Shire Anticipates Vyvanse Approval “Any Day”
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also announces plan to acquire Vyvanse partner New River Pharmaceuticals for $2.6 billion in cash.
You may also be interested in...
Shire Submits Vyvanse sNDA For Adult ADHD
The company plans to announce data from a Phase III trial in adults in the fourth quarter.
Shire Submits Vyvanse sNDA For Adult ADHD
The company plans to announce data from a Phase III trial in adults in the fourth quarter.
Shire Receives FDA “Approvable” Letter On Adult Adderall Product
With an adult filing for Adderall replacement Vyvanse set for mid year, the company is weighing its options, Shire told “The Pink Sheet” DAILY.